Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Ct improvement 85% Improvement Relative Risk Viral clearance 59% Mebendazole  El-Tanani et al.  EARLY TREATMENT  DB RCT Is early treatment with mebendazole beneficial for COVID-19? Double-blind RCT 69 patients in Jordan (January - March 2022) Improved viral clearance with mebendazole (p=0.042) El-Tanani et al., Pharmaceuticals, May 2023 Favors mebendazole Favors control

Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients

El-Tanani et al., Pharmaceuticals, doi:10.3390/ph16060799
May 2023  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
RCT 69 outpatients in Jordan, showing improved viral clearance and CRP with mebendazole.
Authors note that mebendazole, like ivermectin, has been shown to have antiviral activity against multiple viruses.
relative Ct improvement, 85.1% better, RR 0.15, p = 0.04, treatment mean 3.15 (±5.4) n=34, control mean 0.47 (±5.33) n=35, day 3.
risk of no viral clearance, 58.8% lower, RR 0.41, p = 0.43, treatment 2 of 34 (5.9%), control 5 of 35 (14.3%), NNT 12, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
El-Tanani et al., 29 May 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Jordan, peer-reviewed, 5 authors, study period 11 January, 2022 - 12 March, 2022. Contact: (corresponding author),
This PaperIvermectinAll
Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients
Mohamed El-Tanani, Khaled Abdul-Aziz Ahmed, Ashok K Shakya, Wesam G Ammari, Abdel-Elah Al-Shudifat
Pharmaceuticals, doi:10.3390/ph16060799
The outbreak of the COVID-19 pandemic has spread throughout the world, affecting almost all nations and territories. The current double-blind, randomized, placebo-controlled, phase II clinical trial sought to evaluate the clinical efficacy and safety of mebendazole as an adjuvant therapy for outpatients with COVID-19. The patients were recruited and divided into two groups: a Mebendazole-treated group and placebo group. The mebendazole and placebo groups were matched for age, sex, and complete blood count (CBC) with differential and liver and kidney function tests at baseline. On the third day, the C-reactive protein (CRP) levels were lower (2.03 ± 1.45 vs. 5.45 ± 3.95, p < 0.001) and the cycle threshold (CT) levels were higher (27.21 ± 3.81 vs. 24.40 ± 3.09, p = 0.046) significantly in the mebendazole group than in the placebo group on the third day. Furthermore, CRP decreased and CT dramatically increased on day three compared to the baseline day in the mebendazole group (p < 0.001 and p = 0.008, respectively). There was a significant inverse correlation between lymphocytes and CT levels in the mebendazole group (r = -0.491, p = 0.039) but not in the placebo group (r = 0.051, p = 0.888). Mebendazole therapy increased innate immunity and returned inflammation to normal levels in COVID-19 outpatients faster than it did in the placebo group in this clinical trial. Our findings add to the growing body of research on the clinical and microbiological benefits of repurposing antiparasitic therapy, specifically mebendazole, for SARS-CoV-2 infection and other viral infections.
Conflicts of Interest: The authors declare no conflict of interest.
Ahmed, Farag, Boys, Wang, Menendez-Montes et al., FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms, Biomed. Pharmacother, doi:10.1016/j.biopha.2023.114614
Al-Balas, Al-Balas, Alqassieh, Al-Balas, Al-Balas et al., Clinical features of COVID-19 patients in Jordan: A study of 508 patients, Open Respir. Med. J. 2021, doi:10.2174/1874306402115010028
Alamer, Alrashed, Alfaifi, Alosaimi, Alhassar et al., Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: A retrospective study with propensity score matching sensitivity analysis, Curr. Med. Res. Opin, doi:10.1080/03007995.2021.1920900
Andersson, Selvin, Blom, Rubin, Berglund et al., Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway, Sci. Rep, doi:10.1038/s41598-020-68986-0
Blom, Rubin, Berglund, Jarvius, Lenhammar et al., Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition, BMC Res. Notes, doi:10.1186/s13104-019-4273-5
Bosaeed, Alharbi, Hussein, Abalkhail, Sultana et al., Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19, BMJ Open, doi:10.1136/bmjopen-2020-047495
Bosaeed, Alharbi, Mahmoud, Alrehily, Bahlaq et al., Efficacy of favipiravir in adults with mild COVID-19: A randomized, double-blind, multicentre, placebo-controlled clinical trial, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2021.12.026
Braithwaite, Thomas, Thompson, Hydatid disease: The alveolar variety in Australia. A case report with comment on the toxicity of mebendazole, doi:10.1111/j.1445-2197.1985.tb00935.x
Chai, Jung, Hong, Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update, Korean J. Parasitol, doi:10.3347/kjp.2021.59.3.189
Chakraborty, Maity, COVID-19 outbreak: Migration, effects on society, global environment and prevention, Sci. Total Environ, doi:10.1016/j.scitotenv.2020.138882
Chen, Hu, Hood, Zhang, Zhang et al., A novel combination of vitamin C, curcumin and glycyrrhizic acid potentially regulates immune and inflammatory response associated with coronavirus infections: A perspective from system biology analysis, Nutrients, doi:10.3390/nu12041193
Cohen, Early treatment to prevent progression of SARS-CoV-2 infection, Lancet Respir. Med, doi:10.1016/S2213-2600(22)00213-2
Covid-19, Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, National Institutes of Health: Bethesda
De Witt, Gamble, Hanson, Markowitz, Powell et al., Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors, Mol. Med
Domenico, Vanelli, WHO Declares COVID-19 a Pandemic, Acta Biomed
Dorward, Yu, Hayward, Saville, Gbinigie et al., Colchicine for COVID-19 in the community (PRINCIPLE): A randomised, controlled, adaptive platform trial, Br. J. Gen. Pract, doi:10.3399/BJGP.2022.0083
Elayapillai, Ramraj, Benbrook, Bieniasz, Wang et al., Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer, Gynecol. Oncol, doi:10.1016/j.ygyno.2020.10.010
Farag, Wang, Boys, Eitson, Ohlson et al., Identification of Atovaquone, Ouabain and Mebendazole as FDA Approved Drugs Targeting SARS-CoV-2 (Version 4), ChemRxiv, doi:10.26434/chemrxiv.12003930.v4
Ferrari, Seveso, Sabetta, Ceriotti, Carobene et al., Role of time-normalized laboratory findings in predicting COVID-19 outcome, Diagnosis, doi:10.1515/dx-2020-0095
Galal, Ahmed, Shao, Xing, Ali et al., The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study, Adv. Virol, doi:10.1155/2022/3014686
Guerini, Triggiani, Maddalo, Bonù, Frassine et al., Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature, Cancers, doi:10.3390/cancers11091284
Gupta, Sahoo, Singh, Ivermectin: Potential candidate for the treatment of COVID-19, Braz. J. Infect. Dis, doi:10.1016/j.bjid.2020.06.002
Hajjo, Tropsha, A systems biology workflow for drug and vaccine repurposing: Identifying small-molecule BCG mimics to reduce or prevent COVID-19 mortality, Pharm. Res, doi:10.1007/s11095-020-02930-9
Hegazy, El-Azab, Zakaria, Mostafa, El-Ghoneimy et al., from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer, Life Sci, doi:10.1016/j.lfs.2022.120536
Hemphill, Müller, Alveolar and cystic echinococcosis: Towards novel chemotherapeutical treatment options, J. Helminthol, doi:10.1017/S0022149X0928936X
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, Lancet, doi:10.1016/S0140-6736(20)30183-5
Karuppagounder, Zhai, Chen, He, Ratan, The interferon response as a common final pathway for many preconditioning stimuli: Unexpected crosstalk between hypoxic adaptation and antiviral defense, Cond. Med
Keystone, Murdoch, Drugs Five Years Later: Mebendazole, Ann. Intern. Med, doi:10.7326/0003-4819-91-4-582
Khader, Al Nsour, Excess mortality during the COVID-19 pandemic in Jordan: Secondary data analysis, doi:10.2196/32559
Kudo, Kubota, Gotoh, Ishida, Ikadai et al., Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm, Gongylonema pulchrum: In vitro and in vivo studies, Vet. Parasitol, doi:10.1016/j.vetpar.2007.10.005
Law, Akers, Tasnina, Santina, Deutsch et al., Interpretable network propagation with application to expanding the repertoire of human proteins that interact with SARS-CoV-2, doi:10.1093/gigascience/giab082
Li, Thomas, Deutzmann, Majeti, Felsher et al., Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index, Sci. Rep, doi:10.1038/s41598-019-53290-3
Murer, Volle, Andriasyan, Petkidis, Gomez-Gonzalez et al., Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern, Curr. Res. Virol. Sci, doi:10.1016/j.crviro.2022.100019
Panahi, Dadkhah, Talei, Gharari, Asghariazar et al., Can anti-parasitic drugs help control COVID-19? Future Virol, doi:10.2217/fvl-2021-0160
Patel, Zhang, Fullerton, Boelen, Rongvaux et al., The fate and lifespan of human monocyte subsets in steady state and systemic inflammation, J. Exp. Med, doi:10.1084/jem.20170355
Puente, Lago, Subirats, Sanz-Esteban, Arsuaga et al., Imported Mansonella perstans infection in Spain, Infect. Dis. Poverty, doi:10.1186/s40249-020-00729-9
Reis, Silva, Silva, Thabane, Milagres et al., Effect of early treatment with ivermectin among patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2115869
Reis, Silva, Silva, Thabane, Singh et al., Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: The TOGETHER randomized clinical trial, JAMA Netw, doi:10.1001/jamanetworkopen.2021.6468
Rushworth, Hewit, Munnings-Tomes, Somani, James et al., Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment, Br. J. Cancer, doi:10.1038/s41416-019-0681-5
Seitz, Schwerk, Arnold, Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis, Z. Gastroenterol
Sun, Wang, Cai, Hu, Liao et al., Cytokine storm intervention in the early stages of COVID-19 pneumonia, Cytokine Growth Factor. Rev, doi:10.1016/j.cytogfr.2020.04.002
Surapat, Kobpetchyok, Kiertiburanakul, Arnuntasupakul, Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel, Int. J. Clin. Pract, doi:10.1155/2022/3098527
Tolomeo, Colomba, Meli, Cascio, Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome, J. Clin. Pharm. Ther, doi:10.1111/jcpt.13033
Tonelli, Simone, Tasso, Novelli, Boido et al., Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives, Bioorg. Med. Chem, doi:10.1016/j.bmc.2010.02.037
Turner, Shamseer, Altman, Weeks, Peters et al., Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals, Cochrane Database Syst. Rev, doi:10.1002/14651858.MR000030.pub2
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.142
Villoteau, Asfar, Otekpo, Loison, Gautier et al., GERIA-COVID study group, Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients, PLoS ONE, doi:10.1371/journal.pone.0256931
Wang, Guo, Gao, Pu, Li et al., Repurposable drugs for SARS-CoV-2 and influenza sepsis with scRNA-seq data targeting post-transcription modifications. Precis, Clin. Med, doi:10.1093/pcmedi/pbab022
Wilson, Rausch, Mebendazole and alveolar hydatid disease, Ann. Trop. Med. Parasitol, doi:10.1080/00034983.1982.11687523
Worldometer, Cwg, Coronavirus Worldwide Graphs. Available online
Xu, Cao, Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19, Eur. Respir. J, doi:10.1183/13993003.02002-2021
Yamakawa, Yamamoto, Terayama, Hashimoto, Ishihara et al., Japanese Rapid/Living recommendations on drug management for COVID-19, doi:10.1002/ams2.664
Yele, Sanapalli, Mohammed, Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B. 1.1. 7 (Alpha) and P. 1 (Gamma) variant spike glycoproteins: A computational approach, Chem. Zvesti
Zhang, Bochkur, Yazal, Dong, Nguyen et al., Mebendazole potentiates radiation therapy in triple-negative breast cancer, Int. J. Radiat. Oncol. Biol. Phys, doi:10.1016/j.ijrobp.2018.08.046
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop